Premium
Clinical significance of integrin β6 as a tumor recurrence factor in follicular thyroid carcinoma
Author(s) -
Zhuang Zhuonan,
Xu Zhenjie,
Zhou Qian,
Xu Xiaozhou,
Tian Jessie,
Liu Yanfeng,
Guo Sen,
Wang Jiayong,
Xu Kesen
Publication year - 2015
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23780
Subject(s) - immunohistochemistry , follicular phase , thyroid carcinoma , integrin , matrix metalloproteinase , pathology , thyroid , metastasis , clinical significance , medicine , cytoplasm , cancer research , oncology , biology , cancer , microbiology and biotechnology , receptor
Background Overexpression of integrin β6 plays an important role in a variety of malignant tumor invasion and metastasis. Methods The expression levels of integrin β6, matrix metalloproteinase (MMP)‐2 and MMP‐9 were analyzed by immunohistochemistry with human follicular thyroid carcinomas. Then we investigated their correlation with clinical outcomes parameters, relationship, and the survival time. Results The integrin β6 staining was expressed in cellular membrane and cytoplasm of follicular thyroid carcinoma cells. The MMP‐2 and MMP‐9 expressions were mainly found in cellular cytoplasm. In correlation with the clinical outcome parameters of 60 patients, there were significant statistical differences of integrin β6, MMP‐2, and MMP‐9 expression levels in different size of tumor. Integrin β6 and MMP‐9 expressions have significant statistical differences in T classifications. MMP‐2 and MMP‐9 expressions have significant statistical differences in different M classification. Other clinical outcome parameters had no significant statistical differences. Conclusion Integrin β6 expression correlated significantly with MMP‐9 expression, and may be a valuable recurrence indicator for follicular thyroid carcinomas. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1439–1447, 2015